shares of cardiff oncology inc are trading almost 20 higher after hours wednesday following the release of new data from its lead clinical program evaluating onvansertib in combination with standardofcare folfiribevacizumab to treat certain colorectal cancer patients at 529 pm edt the companys shares were trading 1943 higher at 842 a share volume at the time topped 34 million shares the stock finished the days regulartrading session with a 46 loss closing at 705 per share katherine l ruffner the companys chief medical officer said our phase 1b2 trial continues to generate data suggesting that the addition of onvansertib to soc results in an objective response rate and median progressionfree survival that substantially exceed those previously achieved with soc alone she added these impressive results which have remained consistent across both academic and community trial sites highlight the potential for onvansertib to address the unmet need for new secondline therapeutic options to treat patients with krasmutated mcrc